Sa1819 – Retrospective Study on Incidence Rates of Nafld and Advanced Liver Fibrosis in Crohn's Disease and Ulcerative Colitis

Domislović, Viktor; Štromar, Ivana Knežević; Premužić, Marina; Bender, Darija Vranešić; Matašin, Marija; Milinkovic, Anica; Krznarić, Željko

doi:10.1016/s0016-5085(19)37886-2

Cited by 2 publications

(8 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Of these, 92 articles appeared to be potentially pertinent to the study question and were retrieved for further evaluations. Finally, a total of 44 papers fulfilled the eligibility criteria (Figure 1), comprising 14,947 subjects from 18 different countries worldwide 5–7,13,19–58 . There was an excellent agreement between the two investigators for the eligibility judgement (Kappa statistic =0.85).…”

Section: Resultsmentioning

confidence: 88%

“…The pooled prevalence of NAFLD was 34.4% (95% CI 28.0–40.8; I 2 = 96.9%; p <0.001) in 25 studies containing 5223 patients with CD, 5,6,13,21,23–25,30–33,35–40,42,44,46,48,53–55,57 and 28.2% (95% CI 22.0–34.3; I 2 = 95.1%; p <0.001) in 22 studies containing 3101 patients with UC (Table 1 and Figure S2). 5,6,13,20,23–25,30–33,35,36,39,42,44,46,48,50,54,55,57 The pooled OR for NAFLD in patients with CD versus patients with UC was 1.16 (95% CI 0.93–1.44) based on 20 studies, with moderate heterogeneity ( I 2 = 63.9%; p <0.001) but no publication bias (Egger’s test, p =0.65) 5,6,13,23–25,30–33,35,36,39,42,44,46,48,54,55,57 …”

Section: Resultsmentioning

confidence: 99%

“…All papers were published in English. A total of 19 studies were carried out in the European Region (seven in Italy, three in Turkey, two in Germany, two in Portugal, two in Spain, one in Croatia, one in the Netherlands, one in Romania), 5,13,19,21,23,26,28,30,32,35,36,[43][44][45][46]48,52,56,58 18 studies in the Region of the Americas (13 in the USA, three in Canada, one in Mexico and one in Brazil), 6,7,22,24,25,27,29,34,37,[39][40][41]47,[49][50][51]54,55 four studies in the Western Pacific Region (China, Japan, Korea and Taiwan each had an individual study), 31,38,42,49 two studies in the South-East Asian Region (India), 20,53 and one study in the Eastern Mediterranean Region (Qatar). 57 Baseline characteristics, as well as risk of bias assessment, of the included studies are summarised in Table S2.…”

Section: Search Results Study Selection and Characteristicsmentioning

confidence: 99%

“…Figure 3 denotes the prevalence of NAFLD among IBD patients across the world. The pooled prevalence in studies published during 2003-2010, 19,23,41,50 2011-2016, 7,13,22,24,27,28,47,48,56 and 2017-2021 5,6,20,21,25,26,[29][30][31][32][33][34][35][36][37][38][39][40][42][43][44][45][46]49,[51][52][53][54][55]57,58 was 25.2% (95% CI 10.2-40.2; I 2 = 94.4%; p <0.001), 25.9% (95% CI 18.8-33.0; I 2 = 97.4%; p <0.001), and 32.8% (95% CI 27.4-38.2; I 2 = 97.8%; p <0.001), respectively, and the difference was not significant (p =0.258) (Table 1).…”

Section: Pooled Prevalence Of Nafld In Patients With Ibd According To...mentioning

confidence: 99%

“…I 2 = 97.7%; p < 0.001), 5,7,13,20,21,23,[26][27][28][29][30][31][32][33][34][35][36][37][38][39][40][41][42]44,45,[47][48][49][50][51][53][54][55]57,58 four studies used histopathology with a pooled prevalence of 36.2% (95% CI 27.6-44.8; I 2 = 77.0%; p =0.005), 19,25,43,56 two studies used HSI with a pooled prevalence of 34.8% (95% CI 30.9-38.7; I 2 =0.0%; p =0.494), 24,46 two studies used either imaging or HSI with a pooled prevalence of 30.8% (95% CI 10.9-50.6; I 2 = 95.5%; p <0.001), 22,52 and one study used either imaging or histopathology with a prevalence of 12.4% (95% CI 10.8-14.0). 6 The difference in the prevalence rates between different diagnostic methods was significant (p <0.001).…”

Section: Pooled Prevalence Of Nafld In Patients With Ibd According To...mentioning

confidence: 99%

See 4 more Smart Citations

Meta‐analysis: prevalence of, and risk factors for, non‐alcoholic fatty liver disease in patients with inflammatory bowel disease

Zamani

Alizadeh-Tabari

Singh

et al. 2022

Aliment Pharmacol Ther

View full text Add to dashboard Cite

Summary Background Non‐alcoholic fatty liver disease (NAFLD) is found in inflammatory bowel disease (IBD). However, uncertainties remain on the magnitude of the association. Aims To explore systematically the prevalence of, and risk factors for, NAFLD in IBD patients. Methods We searched medical literature using Embase, PubMed, Web of Science, Scopus and ProQuest, from inception to September 30, 2021. We included observational studies reporting the prevalence of NAFLD in ≥50 adult patients with IBD. Diagnosis of NAFLD could be based on imaging, histopathology, and/or hepatic steatosis index. Sex, age, body mass index (BMI), diabetes, hypertension, dyslipidemia, prior surgery (bowel resection), corticosteroids, biologics and immunomodulators were assessed as potential risk factors for NAFLD. Results Of 1893 citations, 44 eligible studies were finally included, comprising 14 947 subjects from 18 different countries. Pooled prevalence of NAFLD was 30.7% (95% confidence interval [CI] 26.5–34.9) in patients with IBD worldwide, which varied regionally. No significant difference was observed in the odds ratio (OR) of NAFLD among Crohn’s disease (CD) patients compared with ulcerative colitis (UC) patients (1.16, 95% CI 0.93–1.44). Risk of NAFLD was almost twice as high in patients with IBD as in healthy subjects (OR 1.96, 95% CI 1.13–3.41). Age (adjusted OR 1.03, 95% CI 1.01–1.05) and BMI (adjusted OR 1.27, 95% CI 1.22–1.32) were statistically significantly associated with increased risk of NAFLD. The pooled prevalence of advanced liver fibrosis in IBD patients with NAFLD was 13.6% (95% CI 7.6–19.7) based on six studies. Conclusion Up to one‐third of patients with IBD experienced NAFLD worldwide. The risk of NAFLD was two times higher in IBD patients versus healthy subjects.

show abstract

Section: Resultsmentioning

confidence: 88%

Section: Resultsmentioning

confidence: 99%

Section: Search Results Study Selection and Characteristicsmentioning

confidence: 99%

Section: Pooled Prevalence Of Nafld In Patients With Ibd According To...mentioning

confidence: 99%

Section: Pooled Prevalence Of Nafld In Patients With Ibd According To...mentioning

confidence: 99%

See 3 more Smart Citations

Meta‐analysis: prevalence of, and risk factors for, non‐alcoholic fatty liver disease in patients with inflammatory bowel disease

Zamani

Alizadeh-Tabari

Singh

et al. 2022

Aliment Pharmacol Ther

View full text Add to dashboard Cite

show abstract

Systematic Review and Meta-Analysis: Prevalence of Non-Alcoholic Fatty Liver Disease and Liver Fibrosis in Patients with Inflammatory Bowel Disease

Navarro,

Gutiérrez-Ramírez,

Tejera-Muñoz

et al. 2023

Nutrients

View full text Add to dashboard Cite

Background: Non-alcoholic fatty liver disease (NAFLD) is a common concomitant condition in patients with inflammatory bowel disease (IBD). We aim to assess the magnitude of this association. Methods: We searched MEDLINE, EMBASE and Scopus libraries for the period up to February 2023 to identify studies reporting cohorts of IBD patients in which NALFLD was evaluated. Results: Eighty-nine studies were analyzed. The overall prevalence of NAFLD was 24.4% (95%CI, 19.3–29.8) in IBD, 20.2% (18.3–22.3) in Crohn’s disease and 18.5% (16.4–20.8) for ulcerative colitis. Higher prevalence was found in male compared to female patients, in full papers compared to abstracts, and in cross-sectional studies compared to prospective and retrospective ones. The prevalence of NAFLD in IBD has increased in studies published from 2015 onwards: 23.2% (21.5–24.9) vs. 17.8% (13.2–22.9). Diagnostic methods for NAFLD determined prevalence figures, being highest in patients assessed by controlled attenuation parameter (38.8%; 33.1–44.7) compared to ultrasonography (28.5%; 23.1–34.2) or other methods. The overall prevalence of fibrosis was 16.7% (12.2–21.7) but varied greatly according to the measurement method. Conclusion: One-quarter of patients with IBD might present with NAFLD worldwide. This proportion was higher in recent studies and in those that used current diagnostic methods.

show abstract

Sa1819 – Retrospective Study on Incidence Rates of Nafld and Advanced Liver Fibrosis in Crohn's Disease and Ulcerative Colitis

Cited by 2 publications

References 0 publications

Meta‐analysis: prevalence of, and risk factors for, non‐alcoholic fatty liver disease in patients with inflammatory bowel disease

Meta‐analysis: prevalence of, and risk factors for, non‐alcoholic fatty liver disease in patients with inflammatory bowel disease

Systematic Review and Meta-Analysis: Prevalence of Non-Alcoholic Fatty Liver Disease and Liver Fibrosis in Patients with Inflammatory Bowel Disease

Contact Info

Product

Resources

About